Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

DRUG3 trials

Sponsors

GlaxoSmithKline Biologicals, Finnish Institute For Health And Welfare, Sciensano

Conditions

COVID-19 infectionHealthy persons and immunocompromised patients (nursing home residentsRespiratory Syncytial Virus Infectionsdialysis patients and kidney- and lung transplant patients) from age 18 till age 105

Phase 3

A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.

CompletedCTIS2023-510196-59-00

GlaxoSmithKline BiologicalsRespiratory Syncytial Virus Infections

Start: 2024-06-15End: 2025-04-18Target: 600Updated: 2025-04-08

Phase 4

COVID-19 vaccine immunological studies in Finland

CompletedCTIS2024-517357-27-00

Finnish Institute For Health And WelfareCOVID-19 infection

Start: 2021-12-07End: 2025-12-17Target: 4000Updated: 2025-02-05

LONGITUDINAL FOLLOW-UP OF SARS-COV-2 IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026

Not yet recruitingCTIS2024-518098-33-01

Sciensanodialysis patients and kidney- and lung transplant patients) from age 18 till age 105, Healthy persons and immunocompromised patients (nursing home residents

Target: 360Updated: 2024-11-25